The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

about

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

Item

http://www.wikidata.org/entity/Q57175806

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

@en

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

@nl

type

Item

label

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

@en

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

@nl

prefLabel

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

@en

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

@nl

P1476

The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

@en

P2093

Daisuke Kotani

http://www.w3.org/2001/XMLSchema#string

Hideaki Bando

http://www.w3.org/2001/XMLSchema#string

Kentaro Sawada

http://www.w3.org/2001/XMLSchema#string

P2860

Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

Fragment Length of Circulating Tumor DNA

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

P304

263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2018.00263

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30062088

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6054927

http://www.w3.org/2001/XMLSchema#string